| Identification | Back Directory | [Name]
CEP-32496 (free base) | [CAS]
1188910-76-0 | [Synonyms]
CS-1683
RXDX-105
AC013773
AC 013773
Agerafenib
RXDX-105 (CEP-32496)
AC-013773. Agerafenib
CEP-32496 (free base)
Agerafenib (CEP-32496)
CEP-32496;CEP 32496;CEP32496
CEP-32496 FREE BASE;AC013773; AC 013773; AC-013773. AGERAFENIB
1-[3-[(6,7-Dimethoxyquinazolin-4-yl)oxy]phenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl]urea
Urea, N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]-
1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea | [Molecular Formula]
C24H22F3N5O5 | [MDL Number]
MFCD22124524 | [MOL File]
1188910-76-0.mol | [Molecular Weight]
517.457 |
| Hazard Information | Back Directory | [Description]
B-Raf is a MAP kinase kinase kinase, which functions downstream of Ras family GTPases to activate MEK1/2 and ERK1/2 signaling.1 Mutations of B-Raf, particularly at Val600, are common in melanomas and melanocytic nevi.1 CEP-32496 is a potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay).2 It blocks B-RafV600E-dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively).2 CEP-32496 binds kinases other than B-Raf but displays selective cytotoxicity for cells expressing B-RafV600E.2 It displays good oral bioavailability in rats, dogs, and monkeys and has single oral dose pharmacodynamics inhibition of both pMEK and pERK in B-RafV600E colon carcinoma xenografts in nude mice.2 | [Uses]
CEP 32496 is an orally active BRAFV600E inhibitor with selective cellular and in vivo antitumor activity. | [in vivo]
Oral administration of Agerafenib (CEP-32496) to Colo-205 tumor xenograft-bearing mice results in significant inhibition of pMEK in tumor cell lysates. For instance, a single 30 mg/kg (po) dose of Agerafenib leads to a 50 and 75% inhibition of normalized pMEK in tumor lysates at the 2 and 6 h postdose time point, respectively (p<0.03), while a 55 mg/kg (po) dose resulted in a 75% to 57% (p<0.03) inhibition of pMEK at 2 through 10 h post administration, with normalization to baseline by 24 h. Agerafenib exhibits an exceptional PK profile in mouse, dog, and cynomolgus monkey. Administration of Agerafenib to beagle dogs (single dose of 1 mg/kg iv and 10 mg/kg po) results in low clearance (CL=5.0 (mL/min)/kg) and excellent bioavailability (%F=100). Similarly, in cynomolgus monkey, the administration of Agerafenib (single dose of 1 mg/kg iv and 10 mg/kg po) leads to high oral exposure due to low clearance (CL=6.7 mL/min/kg) and excellent bioavailability (%F=100)[1]. | [IC 50]
BRafV600E: 14 nM (Kd); Braf: 36 nM (Kd); CRAF: 39 nM (Kd); c-Kit: 2 nM (Kd); Ret: 2 nM (Kd); LCK: 2 nM (Kd); Abl-1: 3 nM (Kd); VEGFR-2: 8 nM (Kd); CSF-1R: 9 nM (Kd); EPHA2: 14 nM (Kd); EGFR: 22 nM (Kd); c-Met: 513 nM (Kd); JAK-2: 4700 nM (Kd); MEK-1: 7100 nM (Kd); MEK-2: 8300 nM (Kd) | [storage]
Store at -20°C | [References]
[1] rowbottom mw1, faraoni r, chao q, campbell bt, lai ag, setti e, ezawa m, sprankle kg, abraham s, tran l, struss b, gibney m, armstrong rc,gunawardane rn, nepomuceno rr, valenta i, hua h, gardner mf, cramer md, gitnick d, insko de, apuy jl, jones-bolin s, ghose ak, herbertz t, ator ma,dorsey bd, ruggeri b, williams m, bhagwat s, james j, holladay mw. identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2 -methylpropan- 2-yl) isoxazol-3-yl) urea hydrochloride (cep-32496), a highly potent and orally efficacious inhibitor of v-raf murine sarcoma viral oncogene homologue b1 (braf) v600e. j med chem. 2012 feb 9;55(3):1082-105. doi: 10.1021/jm2009925. epub 2012 jan 23. |
|
|